- Home
- PHIO
as 11-15-2024 4:00pm EST
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 2.3M | IPO Year: | N/A |
| Target Price: | $36.00 | AVG Volume (30 days): | 41.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.17 - $18.81 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Phio Pharmaceuticals Corp. News
PHIO Breaking Stock News: Dive into PHIO Ticker-Specific Updates for Smart Investing
Newsfile
3 days ago
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Newsfile
11 days ago
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Newsfile
17 days ago
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Newsfile
25 days ago
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Newsfile
a month ago
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Newsfile
a month ago
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Newsfile
a month ago
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Newsfile
a month ago
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
Compare PHIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHIO Phio Pharmaceuticals Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.